Abstract:Summary: The study of a 5-year old patient with a mucopolysaccharidosis different from those already known has given the opportunity to describe the clinical, biochemical and enzymic characteristics of JV-acetylglucosamine-6-sulfate sulfatase deficiency.The patient was delayed physically and mentally, was hyperactive, and had a short attention span. He had fair complexion and very blond, but coarse and excessive hair. He had mild hepato-splenomegaly and dysostosis multiplex, including hypoplastic odontoid process of the atlas, ovoid vertebral bodies, small femoral epiphyses, and modest enlargement of the ribs. He had a mild, bilateral conductive hearing loss. The urine gave a strongly positive spot test with Azur A paper. Quantitative measurement of urinary glycosaminoglycans demonstrated increased excretion and inadequate degradation of heparan sulfate and keratan sulfate. The microscopic examination of the stained peripheral leukocytes revealed metachromatic material which formed a ring on the inner aspect of the cellular membrane in 20% of the lymphocytes. The rate of degradation of 35SO4-labeled intracellular glycosaminoglycans by cutaneous fibroblasts was delayed and inadequate.The measurements of several lysosomal enzymes whose deficiencies are responsible for the known mucopolysaccharidoses gave results within normal ranges. GaIactose-6-sulfate (Gal-6-S), N-acetylgalactosamine-6-sulfate (GalNAc-6-S), and N-acetylglu-cosamine-6-sulfate (GlcNAc-6-S) were prepared with chlorosulfonic acid, according to the method of Suzuki and Strominger (38). After chromatographic purification, aliquots of the three 6-sulfated monosaccharides were reduced with sodium borotritide. Measurements of Gal-6-S sulfatase, GalNAc-6-S sulfatase, and GlcNAc-6-S sulfatase were performed on extracts of normal cultured fibroblasts and of fibroblasts of the propositus, his parents, and several Morquio patients. Additionally, GalNAc-6-S sulfatase and GlcNAc-6-S sulfatase activities were also measured, using as substrate 500 nmol tetrasaccharide obtained from either chon-droitin-6-sulfate or nonradioactive GlcNAc-6-S. The measurement demonstrated that the propositus has a defective GlcNAc-6-S sulfatase activity, but normal activities for Gal-6-S and GalNAc-6-S sulfatase.These findings are in contrast with those found with fibroblast extracts of Morquio patients, since they have low or nondetectable activities of Gal-6-S and GalNAc-6-S sulfatase but normal GlcNAc-6-S sulfatase activity.Extracts of leukocytes and fibroblasts of the propositus' parents, when tested with radioactive or nonradioactive substrates, had normal levels of GalNAc-6-S sulfatase activity but decreased levels of GlcNAc-6-S sulfatase activity (50–60% of normal).Speculation: The possible existence of two different sulfatases, specific for 6-sulfated hexoses with the glucose or galactose configuration, has been suggested (10).The study of a patient with a novel mucopolysaccharidosis, characterized by defective degradation of keratan sulfate and heparan sulfate, has provided the opportunity of describing the clinical and biochemical features of GlcNAc-6-S sulfatase deficiency. These findings confirm that the defective degradation of keratan sulfate and chondroitin-6-sulfate typical of classic Morquio disease is caused by the deficiency of a sulfatase specific for Gal-6-S and GalNAc-6-S.

Evaluation of N-Acetylmannosamine Administration to Restore Sialylation in GNE-Deficient Human Embryonal Kidney Cells

GNE deficiency impairs Myogenesis in C2C12 cells and cannot be rescued by ManNAc supplementation

Glycation Interferes with the Activity of the Bi-Functional UDP- N-Acetylglucosamine 2-Epimerase/ N-Acetyl-mannosamine Kinase (GNE)

Compromised membrane repair in muscle cells from GNE myopathy patients

N-Acetylglucosamine 2-Epimerase from Pedobacter Heparinus: First Experimental Evidence of A Deprotonation/Reprotonation Mechanism

Impact of Food on the Oral Absorption of N‐Acetyl‐D‐Mannosamine in Healthy Men and Women

Novel GNE missense variants impair de novo sialylation and cause defective angiogenesis in the developing brain in mice

Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent

Use of pure recombinant human enzymes to assess the disease‐causing potential of missense mutations in urea cycle disorders, applied to N‐acetylglutamate synthase deficiency

Understanding pathophysiology of GNE myopathy and current progress towards drug development

Induced Muscle and Liver Absence of Gne in Postnatal Mice Does Not Result in Structural or Functional Muscle Impairment

N-Acetylglucosamine-6-Sulfate Sulfatase in Man: Deficiency of the Enzyme in a New Mucopolysaccharidosis

Efficacy Confirmation Study of Aceneuramic Acid Administration for GNE Myopathy in Japan.

Ion Mobility QTOF-MS Untargeted Lipidomics of Human Serum Reveals a Metabolic Fingerprint for GNE Myopathy

Engineering intracellular CMP-sialic acid metabolism into insect cells and methods to enhance its generation

A Novel N-Tetrasaccharide In Patients With Congenital Disorders Of Glycosylation, Including Asparagine-Linked Glycosylation Protein 1, Phosphomannomutase 2, And Mannose Phosphate Lsomerase Deficiencies

Enzymatic production of N-acetylneuraminic acid: advances and perspectives

Phase I Clinical Trial Results of Aceneuramic Acid for GNE Myopathy in Japan

-acetylglucosamine supplementation fails to bypass the critical acetylation of glucosamine-6-phosphate required for replication and invasion

GNE Myopathy: Etiology, Diagnosis, and Therapeutic Challenges

Gene delivery corrects N-acetylglutamate synthase deficiency and enables insights in the physiological impact of L-arginine activation of N-acetylglutamate synthase